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patients who receive similar local therapy of primary disease (median 
survival 12 vs. 8 months).
Conclusions: For NSCLC patients with brain as a solitary organ site of 
metastasis and a single brain metastasis, radiotherapy or resection for 
primary lung disease markedly improves median survival. For those 
with extracranial solitary organ sites of metastases, local therapy of pri-
mary thoracic disease improves survival, but this beneﬁt is lost in those 
who survive beyond one year. Patients with extracranial metastases 
rarely received local therapy for metastases, whereas brain metastasis 
patients invariably do. Our results suggest a potential beneﬁt and need 
for a prospective study of surgical resection or radiotherapy to all vis-
ible disease in patients with oligometastatic NSCLC. 
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Hypofractionated stereotactic body radiotherapy in patients with 
peripherally or centrally located medically inoperable stage I or 
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Background: To evaluate the therapeutic efﬁcacy and treatment-
related toxicity of image-guided hypofractionated stereotactic body 
radiotherapy (SBRT) in patients with peripherally or centrally located, 
medically inoperable stage I or isolated recurrent NSCLC. 
Methods: Subjects had pathologically conﬁrmed stage I (n=49) or 
isolated recurrent (n=24) NSCLC. Among 73 patients, 25 patients had 
centrally located lesions deﬁned as within 2 cm of bronchial tree, major 
vessels, esophagus, heart and other mediastinal structures but no direct 
invasion. Internal gross target volume was delineated using maximal 
intensity projection created by combining the data from a 4-D CT da-
taset at different respiratory phases. The clinical target volume was the 
internal gross target volume plus an 8-mm margin, and a 3-mm setup 
uncertainty margin was added to determine the planning target volume. 
For each fraction the patient was aligned using in-room CT-on-rails. 
The prescribed dose was 50 Gy to PTV at daily 12.5 Gy/fraction for 4 
contiguous days. Dose constraint of major mediastinal critical organs 
was 40 Gy less than 10 cc except for esophagus in which 40 Gy was 
limited to less than 1 cc. 
Results: Median follow-up was 18 months (3-28 months). The overall 
progression-free survival rate at the treated site was 95.9%. For stage I 
disease, the complete response (CR), partial response (PR) and stable 
disease (SD) rate were 33%, 35% and 31% respectively. There was no 
signiﬁcant difference in response rate between stage Ia (n=42) and Ib 
(n=7). Two patients (4.1%) developed mediastinal lymph node metasta-
sis. For isolated recurrent disease, the CR, PR and SD rate were 45.8%, 
33.3%, and 12.5% respectively. Mediastinal lymph node metastasis 
happened in three patients (12.5%). There was 6.1% grade II but no 
grade III and above radiation pneumonitis in stage I disease. Three 
patients with recurrent disease had worse dyspnea after SBRT and 
one patients needed nasonal oxygenation. No esophagitis was noted. 
22.8% of patients developed grade II dermatitis at the treated site that 
appears related to the dose (>35 Gy) and volume of the skin treated. 
Three patient developed chronic skin scar and ﬁve patients had chronic 
mild neurogenic chest pain due to intercostal nerve injury. There was 
no increased toxicity noted in centrally located lesions compared with 
peripherally located lesions.
Conclusions: Image-guided SBRT using 50 Gy in four fractions 
achieved excellent local progression-free survival rate with minimal 
toxicity in peripherally or centrally located stage I or isolated recurrent 
NSCLC. Long-term follow up and further studies are needed to evalu-
ate the toxicity of centrally located lesions and higher dose volume 
constraints to critical structures. 
PD5-2-7 Clinical Data from Radiation Therapy, Thu, 12:30 - 14:15
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Background: Radiotherapy is the cornerstone treatment for unresect-
able LA-NSCLC. Outcomes with standard RT scheduling in this patient 
subgroup are poor and new approaches like altered fractionation were 
studied. Even though many trials investigated the value of these new 
strategies, their results were inconsistent. We performed a meta-analy-
sis of those trials to try to clarify this matter.
Methods: We performed a thorough literature search to identify phase 
III randomized trials where standard RT was compared with an altered 
RT fractionation in the treatment of LA-NSCLC. The trials were 
analysed for any relevant end point and a meta-analysis of the selected 
trials was performed.
Results: We found 6 trials with n=1484 (n=793 for HFRT and n=691 
for SRT). An absolute improvement in mortality rate of 4.2% with 
HFRT was shown: 90.7% for SRT vs 86.5% for HFRT (p<0.02), with 
a HR=0.65 (CI 95%: 0.47-0.90). Results persist even excluding RTOG 
8808 and CHART. Two year survival was also improved (31.8 vs 
26.1%). Response rate (data available from 2 studies) were similar: 
60.8 vs. 52.5%; HFRT was associated with a reduction of 28% in local 
failures (HR: 0.72, CI: 0.56-0.93). Toxicity: HFRT produced a signiﬁ-
cantly increased incidence of Grade 3 and 4 esophagitis (18.1 vs. 8.7%, 
p<0.001); but grade 3/4 pneumonitis was less frequent with HFRT (8.2 
vs. 11.6%, p<0.02). 
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Conclusions: This meta-analysis shows a modest but signiﬁcant 
improvement in overall survival and local failures at the expense of a 
clearly increased severe esophagitis. Difﬁculties of increased treat-
ment frequency and the continuous therapy over weekends make these 
strategies hard to adopt. On the other hand, due to the heterogeneity of 
altered fractionation modalities among the trials included, our results 
should be considered with caution and must be interpreted as an hy-
pothesis generator.
TRIAL n HFRT type Chemotherapy Median OS p
Ball 204 60 Gy in 3 wks Weekly CBDCA 14.7 vs 15.4 ns
Saunders 
(CHART) 563
54 Gy in  
12 consecutive days No CT 16.5 vs 13 0.008
Bonner 99 60 Gy in 4 wks split CDDP-VP16 11.6 vs 8.6 ns
ECOG 2597 112 57.6 Gy in  13 consecutive days
CBDCA-paclitaxel 
before RT 20.3 vs 14.9 ns
RTOG 8808 458 69.6 Gy in 6 wks CDDP-VBL 12 vs 11.4 ns
Schild 234 60 Gy in 4 wks split CDDP-VP16 14 vs 15 ns
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brain metastases treated with whole brain radiation therapy: 
pooled data from two randomized trials
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Background: A commonly used prognostic classiﬁcation for brain 
metastasis patients is the Recursive Partitioning Analysis (RPA) clas-
siﬁcation developed with data from patients enrolled in RTOG trials 
from 1979 to 1993, which includes performance status, age, presence 
of extracranial metastasis and control of primary disease. The purpose 
of the current study was to determine if additional variables are signiﬁ-
cant independent predictors of survival in NSCLC patients with brain 
metastases.
Methods: In protocol 9801, 401 pts with brain metastases from any 
primary tumor were randomized to whole brain radiation therapy 
(WBRT, 30 Gy/10 fractions) or WBRT+MGd, 5 mg/kg qd x 10 days. 
The subgroup of 251 pts with NSCLC is included in this analysis. 
In protocol 0211, 554 pts with brain metastases from NSCLC were 
randomized to the same treatments. In both studies, eligibility included 
a KPS≥70, no liver metastases, and ≤1 site of extracranial metastasis. 
Univariate and stepwise multivariate Cox analyses were carried out 
using baseline clinical variables, laboratory values, neurocognitive test 
scores and survival follow-up data. Hazard ratios (HR) less than 1 favor 
the speciﬁed group.
Results: 805 patients, with a median age of 59 years, 44.6% female, 
55.4% male, 53.3% adenocarcinoma, 19.3% NSCLC, not otherwise 
speciﬁed (NOS), 13.4% squamous cell, 10.6% large cell, 0.9% bron-
choalveolar, 19.7% single brain metastasis, 80.3% multiple brain me-
tastases, 47% extracranial metastases, and 84% presentation with neu-
rologic deﬁcits were randomized to WBRT (N=403) or WBRT+MGd 
(N=402). Time to neurologic progression in the WBRT+MGd group 
was 15.4 months, signiﬁcantly longer than the 9.0 months for the 
WBRT alone group, p=0.016, HR=0.74 (95% CI 0.57-0.95). Median 
survival overall was 5.5 months, without statistically signiﬁcant differ-
ence between treatment groups. Univariate predictors of survival were 
age, performance status, sex, histology, geographic region, low LDH, 
high LDH, low albumin, low Hgb, impaired memory (HVLT recall 
and recognition tests), verbal ﬂuency (COWA test), executive function 
(Trailmaking test B), number of impaired neurocognitive tests, and 
smoking history. RPA class was borderline predictive in a univariate 
model (HR=1.27, P=0.056 for RPA class II vs I). In a stepwise model 
of all variables, age ≥65 (HR=1.34, P=0.005), KPS 90-100 (HR=0.70, 
P<0.001), multiple brain metastases (HR=1.27, P=0.035), presence 
of extracranial metastases (HR=1.21, P=0.036), male sex (HR=1.34, 
P=0.001), non-small-cell histology (NOS) (HR=1.37, P=0.005), 
Canada (HR=1.28, P=0.013), high baseline LDH (HR=1.39, P=0.023), 
low baseline LDH (HR=0.49, P=0.046), low baseline albumin (HR 
1.64, P<0.001), current smoker (HR=1.29, P=0.009) were independent 
predictors of survival. 
Conclusions: In two large randomized trials of patients with NSCLC 
and brain metastases, older age, poorer performance status, multiple 
brain metastases, presence of extracranial metastases, male sex, 
elevated LDH and albumin, current smoking status, and residence in 
Canada were signiﬁcant predictors of shorter survival. These variables 
may provide more predictive power than RPA class for future random-
ized trials in NSCLC patients with brain metastases that have survival 
as an endpoint.
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Objectives: The extend of lymph node involvement in patients with 
non-small cell lung cancer (NSCLC) is the most important prognostic 
factor and inﬂuences multimodality treatment. We studied safety, ac-
curacy and characteristics of intraoperative ultrasound (US) guided sys-
tematic mediastinal nodal dissection in patients with resected NSCLC.
Methods: Intraoperative hand held ultrasound probe was used in sys-
tematic mediastinal nodal dissection in 54 patients after radical surgery 
for NSCLC. Mapping of the lymph nodes by their number and station 
followed by histopathologic evaluation was performed. Data were com-
pared with 58 patients who underwent lung resections and systematic 
mediastinal nodal dissection for NSCLC within the same time period at 
our institution. Statistical analysis was carried out.
Results: The surgical procedure used depended on the extent of the 
disease, as well as the cardiopulmonary reserve of the patients and was 
comparable in both groups. Operating time was prolonged for 12 (6 
- 20) minutes in patients with US guided mediastinal nodal dissection, 
but number and stations of evaluated lymph nodes was signiﬁcantly 
higher (p>0.001) at the same group of patients. Skip nodal metastases 
were found in 24% of patients without N1 nodal involvement. Standard 
staging system seemed to be improved in US guided mediastinal 
lymphadenectomy patients. Complications rate showed no difference 
between analyzed groups of patients.
Conclusion: Higher number and location of analyzed mediastinal 
nodal stations in patients with resected NSCLC using hand held ultra-
sound probe suggested to be of great oncology signiﬁcance. Procedure 
